Screening of JAK2 V617F mutation in multiple myeloma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Screening of JAK2 V617F mutation in multiple myeloma

Published:2006-07-27 Issue:10 Volume:20 Page:1912-1913
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Fiorini A,Farina G,Reddiconto G,Palladino M,Rossi E,Za T,Laurenti L,Giammarco S,Chiusolo P,Leone G,Sica S

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/2404332.pdf

Reference8 articles.

1. Baxter EJ, Scott LM, Campbell PJ, East C, Fourclas N, Swanton S, et al., Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–1061.

2. Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, Stoffregen E et al. The JAK2 activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukaemia, but not in acute lymphoblastic leukaemia or chronic lymphocytic leukaemia. Blood 2005; 106: 3377–3379.

3. Sulong S, Case M, Minto L, Wilkins B, Hall A, Irving J . The V617F mutation in JAK2 is not found in childhood acute lymphoblastic leukemia. BrJ Haematol 2005; 130: 964–972.

4. Melzner I, Weniger MA, Menz CK, Moller P . Absence of the JAK2 V617F activating mutation in classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma. Leukemia 2006; 20: 157–158.

5. Scott LM, Campbell PJ, Baxter EJ, Todd T, Stephens P, Edkins S et al. The V617F JAK2 mutation is uncommon in cancers and myeloid malignancies other than the classic myeloproliferative disorders. Blood 2005; 106: 2920–2921.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pathogenic signaling in multiple myeloma;Seminars in Oncology;2022-02

2. The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors;Cancer Medicine;2020-07-06

3. Anti‐myeloma potential of ruxolitinib in co‐existing JAK2V617F ‐positive smouldering myeloma and polycythaemia vera;British Journal of Haematology;2020-02-20

4. Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple Myeloma;Clinical Lymphoma Myeloma and Leukemia;2019-07

5. STAT3: A Promising Therapeutic Target in Multiple Myeloma;Cancers;2019-05-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3